Table 3 Blood and Lipid Profiles for Each Visit by Group.

From: A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury

 

Baseline

Month 1

Month 2

Month 3

Month 4

p value

Control

Treatment

Control

Treatment

Control

Treatment

Control

Treatment

Control

Treatment

Group

Visit

Interaction

n

8

10

8

10

8

10

8

10

8

10

—

—

—

Triglyceride (mg/dl)

189 ± 75

204 ± 70

178 ± 76

128 ± 41

166 ± 78

120 ± 45*

156 ± 58

145 ± 60

183 ± 79

122 ± 55*

NS

0.01

0.001

HDL-C (mg/dl)

35 ± 7

38 ± 8

37 ± 10

47 ± 8

36 ± 10

49 ± 9‡

35 ± 6

46 ± 9

35 ± 7

47 ± 12†

0.05

0.01

0.05

LDL-C (mg/dl)

107 ± 20

131 ± 20†

115 ± 23

114 ± 23

115 ± 30

111 ± 28

113 ± 25

111 ± 21

46 ± 13

106 ± 16

NS

0.01

0.05

VLDL-C (mg/dl)

38 ± 15

41 ± 14

36 ± 15

26 ± 8

33 ± 16

24 ± 9*

31 ± 12

29 ± 12

37 ± 16

25 ± 11§

NS

0.001

0.01

Total Cholesterol (mg/dl)

180 ± 20

210 ± 30†

188 ± 31

187 ± 29

185 ± 34

184 ± 40

180 ± 31

186 ± 24

176 ± 21

177 ± 28

NS

0.01

0.05

Glucose (mg/dl)

88 ± 14

86 ± 11

88 ± 6

90 ± 10

87 ± 9

91 ± 6

91 ± 13

84 ± 8

86 ± 8

87 ± 7

NS

NS

NS

Insulin (mIU/ml)

20 ± 15

12 ± 10

16 ± 16

19 ± 13

11 ± 7

12 ± 7

14 ± 8

14 ± 10

18 ± 21

12 ± 8

NS

NS

NS

  1. Data are expressed as group mean ± SD. HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; VLDL-C: very low-density lipoprotein cholesterol. *p = 0.10; †p < 0.05; ‡p < 0.01; §p = 0.06.
Back to article page